Could a synthetic cannabis drug soothe Alzheimer's agitation?

NCT ID NCT04516057

First seen Jan 28, 2026 · Last updated May 15, 2026 · Updated 16 times

Summary

This study tests whether nabilone, a synthetic cannabinoid already approved for nausea, can safely reduce agitation in people with Alzheimer's disease. Agitation is common and distressing, and current treatments have limited effectiveness and side effects. About 112 participants will receive either nabilone or a placebo for 8 weeks, with follow-up for another 8 weeks. Researchers will also check effects on mood, pain, nutrition, and caregiver stress.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre for Addiction and Mental Health

    RECRUITING

    Toronto, Ontario, Canada

    Contact Email: •••••@•••••

  • London Health Sciences Centre

    RECRUITING

    London, Ontario, N6A 5W9, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ontario Shores Centre for Mental Health Sciences

    RECRUITING

    Whitby, Ontario, L1N 5S9, Canada

    Contact Email: •••••@•••••

  • St. Michael's Hospital

    RECRUITING

    Toronto, Ontario, Canada

    Contact Email: •••••@•••••

  • Sunnybrook Health Sciences Centre

    RECRUITING

    Toronto, Ontario, M4N 3M5, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Calgary

    RECRUITING

    Calgary, Alberta, T2N 4N1, Canada

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.